Sensei Biotherapeutics, a clinical stage immuno-oncology company, provided updated dose escalation data from the SNS-101 clinical study, showing favorable safety and PK profile in both monotherapy and in combination with PD-1 blockade. The company expects topline efficacy and biomarker data for both arms of the study in Q2 2024, ahead of previous guidance. With a strong balance sheet and cash runway into the fourth quarter of 2025, Sensei Biotherapeutics is focused on maximizing the value of SNS-101 and other novel product candidates.
“As we enter 2024, we are excited about the progress of our anti-VISTA antibody, SNS-101, which has shown promising results in our clinical trials,” said John Celebi, President and CEO of Sensei Biotherapeutics. “We are looking forward to an exciting year ahead, with plans to share key data earlier than anticipated. Our team is also preparing for an end-of-Phase 1 meeting with the FDA later this year to outline our strategic plans for the future.”
Highlights from the SNS-101 clinical study include the enrollment of 33 patients in the dose escalation phase, with favorable safety profiles observed in both monotherapy and combination arms. Sensei Biotherapeutics plans to report topline data for both arms in Q2 2024, with additional data expected by the end of the year. The company also announced plans to enroll additional patients in specific tumor types to further optimize the Phase 2 trial design.
In addition to the clinical study updates, Sensei Biotherapeutics highlighted collaborations with the National Cancer Institute and Regeneron to support the development of SNS-101. The company has also made key appointments, including a new Chief Medical Officer and Chief Business Officer, to strengthen its leadership team.
Financially, Sensei Biotherapeutics reported a cash position of $65.8 million as of December 31, 2023, which is expected to fund operations into the fourth quarter of 2025. Research and Development expenses decreased in 2023, primarily due to lower manufacturing-related costs and personnel expenses following a restructuring in December 2022.
Overall, Sensei Biotherapeutics is poised for a productive year in 2024, with significant advancements in its clinical programs and a strong financial position to support its growth initiatives.
Read More Business News
